Zymeworks Inc. (ZYME) Stock Analysis and Metrics

Zymeworks

NASDAQ: ZYME

$22.87 ▼ -0.25 (-1.08%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.70 Bn

P/E-16.61

P/S20.98

Div. Yield0.00

Revenue Growth (1y) (Qtr)-91.12

Add ratio to table…

About

Zymeworks Inc. is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel multifunctional biotherapeutics to improve the standard of care for difficult to treat conditions including cancer, inflammation, and autoimmune disease. The company employs an asset and royalty aggregation strategy to optimize future milestone and royalty cash flows while retaining flexibility to return capital to stockholders. ZW191 targets folate receptor alpha for ovarian, endometrial, and non small cell lung cancer. ZW251 targets glypican 3 for hepatocellular carcinoma. ZW220 targets NaPi2b for non small cell lung cancer, and ovarian cancer. Preclinical programs feature ZW209 a trispecific T cell engager targeting DLL3. ZW1528 is a bispecific antibody targeting IL 4Rα, and IL 33 for autoimmune and inflammatory diseases. Zymeworks relies on its proprietary Azymetric platform for multispecific antibodies, its EFECT platform for Fc modulation, and its drug conjugate platforms for toxin delivery to build these candidates. These platforms enable the design of bispecific and trispecific molecules that can engage multiple targets simultaneously.

Zymeworks generates revenue primarily through upfront payments, milestone payments, and tiered royalties from its collaboration and licensing agreements with pharmaceutical partners. As of December 31, 2025, the company had received $491 million in upfront and milestone payments from Jazz and BeOne related to zanidatamab. Under the Jazz collaboration, Zymeworks is eligible for tiered royalties of 10 to high teens % on global net sales outside Asia, excluding Japan, Australia, and New Zealand, up to $2 billion, and 20% on sales above $2 billion. Under the BeOne collaboration, tiered royalties range from mid single to mid double digit % on annual net sales in Asia, excluding Japan, Australia, and New Zealand, up to $1 billion, and 19.5% on sales above $1 billion. Platform partnerships with BMS, GSK, Daiichi Sankyo, J&J, and Merck have contributed $233.4 million in upfront and milestone payments as of the same date. The Royalty Pharma loan arrangement provided $250 million in upfront cash in exchange for a portion of future Ziihera royalties. These payments provide non dilutive funding that supports research and development activities while preserving financial flexibility for capital allocation decisions.

Zymeworks occupies a niche in the biotechnology sector as a developer of multispecific antibody and antibody drug conjugate platforms competing with larger firms such as Roche, Novartis, AstraZeneca, and Merck, as well as specialized biotechs like Seagen and MacroGenics. In oncology, the company's HER2 targeted asset Ziihera faces competition from established therapies such as Herceptin, Perjeta, Phesgo, Kadcyla, Tykerb, Nerlynx, Enhertu, Tukysa, Margenza, pyrotinib, disitamab vedotin, anbenitamab, and various biosimilars. For FRα directed programs, Zymeworks competes with Elahere and emerging antibody drug conjugates such as Rina S, AZD5335, sofetabart mipitecan, IMGN151, and ABBV901. GPC3 directed candidates are measured against ADCs such as MRG006, BC2027, cell therapies, T cell engagers, radioconjugates, and monoclonal antibodies. IL 4Rα and IL 33 targeted molecules compete with bispecific therapies such as AK139, and other IL 4Ra ST2 bispecifics. Zymeworks' advantages derive from its proprietary protein engineering capabilities, its integrated drug development engine, and its ability to generate non dilutive funding through royalty partnerships. The company's intellectual property portfolio includes more than 300 issued patents covering its therapeutic antibody product candidates and platform technologies.

The company's customer base consists of pharmaceutical and biotechnology partners that license its platforms and product candidates including Jazz Pharmaceuticals, BeOne Medicines Ltd., Bristol Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Johnson & Johnson, and Merck. Jazz Pharmaceuticals holds worldwide rights for zanidatamab, excluding Asia Pacific territories, and leads development and commercialization of the product in those regions. BeOne Medicines Ltd. possesses exclusive rights for zanidatamab in Asia, excluding Japan, as well as in Australia and New Zealand. Bristol Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Johnson & Johnson, and Merck have licensed various of Zymeworks antibody drug conjugate multispecific and Fc engineering platforms for their own research and development programs. These partnerships have generated significant upfront milestone and royalty payments, and provide Zymeworks with access to external funding and expertise.

Investment Thesis

▲ Bull case

Zymeworks Inc. is positioned to benefit from a significant near-term catalyst with the potential approval of zanatumab (Zahera) in first-line GEA, which could trigger milestone payments totaling $440 million from Jazz and BeiGene across the U.S., Europe, Japan, and China. The CFO explicitly stated that existing cash resources of $403.8 million as of March 31, 2026, combined with these anticipated milestone payments, are expected to fund planned operations beyond 2028 without relying on additional royalties or future partnerships. This provides a substantial cash runway that reduces near-term financing risk and allows the company to continue investing in its pipeline while returning capital to shareholders via the ongoing share repurchase program, which has already retired over 10% of common shares at a meaningful discount to current market price. The disciplined capital allocation framework, underscored by the CFO’s focus on ROI and transparent reporting of invested capital returns, suggests that management is prioritizing long-term per-share value creation over short-term earnings volatility, which the market may be overlooking amid the current net loss expansion driven by nonrecurring 2025 milestones.
The pan-RAS ADC platform represents a structurally differentiated opportunity that addresses a core limitation of small-molecule RAS inhibitors—systemic toxicity—by leveraging Zymeworks’ proprietary TOPA payload to achieve sustained tumor-targeted pathway inhibition with minimal off-target effects. Preclinical data presented at AACR demonstrated durable RAS pathway inhibition in tumors out to 14 days post-dose, with clear differentiation from normal tissues in distribution and biological effect, while showing no observed body weight loss, skin toxicity, or GI toxicity in nonhuman primates at doses up to 120 mg/kg. This therapeutic index—where efficacy is achieved at ~1 mg/kg in xenograft models but tolerability extends to 120 mg/kg—creates a 120-fold window that far exceeds typical ADC profiles and supports the potential for combination regimens and broader patient applicability. The company’s strategy of advancing three distinct pan-RAS ADC candidates (ZW439, ZW427, ZW418) targeting Claudin 18.2, L1CAM, and PTK7 across pancreatic, colorectal, and non-small cell lung cancers simultaneously creates optionality and reduces reliance on any single asset, with management indicating they are well positioned to enter IND-enabling activities shortly, a timeline not heavily promoted but implied by their readiness to proceed with manufacturing and CMC preparations.
ZW191, the folate receptor alpha-targeting ADC, exhibits a compelling benefit-risk profile in heavily pretreated ovarian and endometrial cancer patients, with disease control rates of 94% and 80% respectively and confirmed ORR of 61% and 57% in the clinically relevant dose range, despite activity being observed regardless of FRα expression level—including low or negative tumors. This breadth of activity, supported by preclinical combination data showing synergy with standard-of-care therapies and a favorable tolerability profile dominated by manageable cytopenias and GI events, suggests ZW191 could outperform existing FRα ADCs in both efficacy and safety, particularly as the company explores dose optimization in the 60-patient fully enrolled cohort. The fact that ZW191 is being evaluated at higher dose intensities than competitors without proportional safety deterioration indicates a potential to deliver superior dose-dependent efficacy at scale, a differentiator that could drive partnership interest or support accelerated development in earlier lines of therapy, yet management has remained deliberately vague about partnership timelines, implying they may be preserving optionality for a favorable deal structure rather than rushing into suboptimal terms.

Zymeworks Inc. is positioned to benefit from a significant near-term catalyst with the potential approval of zanatumab (Zahera) in first-line GEA, which could trigger milestone payments totaling $440 million from Jazz and BeiGene across the U.S., Europe, Japan, and China. The CFO explicitly stated that existing cash resources of $403.8 million as of March 31, 2026, combined with these anticipated milestone payments, are expected to fund planned operations beyond 2028 without relying on additional royalties or future partnerships. This provides a substantial cash runway that reduces near-term financing risk and allows the company to continue investing in its pipeline while returning capital to shareholders via the ongoing share repurchase program, which has already retired over 10% of common shares at a meaningful discount to current market price. The disciplined capital allocation framework, underscored by the CFO’s focus on ROI and transparent reporting of invested capital returns, suggests that management is prioritizing long-term per-share value creation over short-term earnings volatility, which the market may be overlooking amid the current net loss expansion driven by nonrecurring 2025 milestones.
The pan-RAS ADC platform represents a structurally differentiated opportunity that addresses a core limitation of small-molecule RAS inhibitors—systemic toxicity—by leveraging Zymeworks’ proprietary TOPA payload to achieve sustained tumor-targeted pathway inhibition with minimal off-target effects. Preclinical data presented at AACR demonstrated durable RAS pathway inhibition in tumors out to 14 days post-dose, with clear differentiation from normal tissues in distribution and biological effect, while showing no observed body weight loss, skin toxicity, or GI toxicity in nonhuman primates at doses up to 120 mg/kg. This therapeutic index—where efficacy is achieved at ~1 mg/kg in xenograft models but tolerability extends to 120 mg/kg—creates a 120-fold window that far exceeds typical ADC profiles and supports the potential for combination regimens and broader patient applicability. The company’s strategy of advancing three distinct pan-RAS ADC candidates (ZW439, ZW427, ZW418) targeting Claudin 18.2, L1CAM, and PTK7 across pancreatic, colorectal, and non-small cell lung cancers simultaneously creates optionality and reduces reliance on any single asset, with management indicating they are well positioned to enter IND-enabling activities shortly, a timeline not heavily promoted but implied by their readiness to proceed with manufacturing and CMC preparations.
ZW191, the folate receptor alpha-targeting ADC, exhibits a compelling benefit-risk profile in heavily pretreated ovarian and endometrial cancer patients, with disease control rates of 94% and 80% respectively and confirmed ORR of 61% and 57% in the clinically relevant dose range, despite activity being observed regardless of FRα expression level—including low or negative tumors. This breadth of activity, supported by preclinical combination data showing synergy with standard-of-care therapies and a favorable tolerability profile dominated by manageable cytopenias and GI events, suggests ZW191 could outperform existing FRα ADCs in both efficacy and safety, particularly as the company explores dose optimization in the 60-patient fully enrolled cohort. The fact that ZW191 is being evaluated at higher dose intensities than competitors without proportional safety deterioration indicates a potential to deliver superior dose-dependent efficacy at scale, a differentiator that could drive partnership interest or support accelerated development in earlier lines of therapy, yet management has remained deliberately vague about partnership timelines, implying they may be preserving optionality for a favorable deal structure rather than rushing into suboptimal terms.

▼ Bear case

Zymeworks Inc.’s financial results reveal a concerning deterioration in core operating performance, with total revenue declining 91% year-over-year to $2.4 million in Q1 FY26 from $27.1 million in Q1 FY25, driven not only by the lapping of nonrecurring clinical milestones but also by continued declines in development support and drug supply revenue from Jazz, indicating weakening momentum in its most established partnership. The CFO acknowledged that current-year revenue reflects only ongoing collaboration activity and increased royalty revenue, which remains minimal and highly dependent on future commercial sales of zanatumab—sales that have not yet materialized and face potential pricing pressure ex-U.S., as indirectly noted by Jazz’s MFN pricing headwinds commentary. Despite a $403.8 million cash position, the net loss widened to $44.2 million in Q1 FY26 from $22.6 million in Q1 FY25, primarily due to the revenue decline, and while the company cites disciplined OpEx management, the increase in unallocated costs related to leadership transition and only partial offset from reduced third-party program costs suggest underlying cost discipline may be eroding as the organization scales its leadership and R&D investments simultaneously.
The pan-RAS ADC platform, while scientifically intriguing, faces substantial translational hurdles that management did not adequately address, including the inherent complexity of developing ADC payloads targeting intracellular proteins like RAS, which requires efficient internalization, endosomal escape, and cytosolic delivery—none of which were quantified in the preclinical data presented. The company’s reliance on DAR-8 ADCs to estimate relative payload delivery and their avoidance of direct mole-to-mole comparisons with small-molecule inhibitors suggest a lack of confidence in demonstrating comparable intracellular target engagement, raising questions about whether the observed tumor accumulation and pathway inhibition (via DUSP6 levels) truly translate to meaningful antiproliferative effects at clinically achievable doses. Furthermore, the focus on xenograft models, which lack human stroma and immune components, limits the generalizability of the durability claims, and the absence of any discussion regarding payload stability, linker efficacy in vivo, or manufacturing scalability for novel pan-RAS inhibitors indicates that these programs remain highly speculative, with IND filing timelines for 2027 implicitly acknowledged through the deferral of ZW1528 and no concrete dates provided for the RAS ADCs despite claims of being “well positioned.”
ZW191’s clinical activity, while encouraging in heavily pretreated populations, may not be sufficient to support broad commercial viability, particularly given the lack of biomarker-driven patient selection and the observation of activity regardless of FRα expression, which complicates trial design, increases development costs, and risks dilution of efficacy signals in larger Phase 2/3 studies. The company’s acknowledgment that dose optimization is ongoing in a 60-patient cohort—despite prior reporting of full enrollment—suggests uncertainty in defining the optimal therapeutic window, and while they cite flexibility to refine tolerability without compromising activity, the absence of any discussion regarding combination trial initiation or partnership pursuit beyond vague statements about evaluating options implies internal resource constraints may limit their ability to independently generate the robust data package needed for regulatory approval or value-accretive external collaboration. Furthermore, the broader TriTCE and pasotuxizumab programs, while cited as long-term value drivers, remain preclinical or early-stage with no near-term data catalysts, and the company’s repeated emphasis on optionality and partnership dependence for advancing assets like ZW191 signals a lack of conviction in solo execution, which could deter investors seeking self-sufficient growth engines.

Zymeworks Inc.’s financial results reveal a concerning deterioration in core operating performance, with total revenue declining 91% year-over-year to $2.4 million in Q1 FY26 from $27.1 million in Q1 FY25, driven not only by the lapping of nonrecurring clinical milestones but also by continued declines in development support and drug supply revenue from Jazz, indicating weakening momentum in its most established partnership. The CFO acknowledged that current-year revenue reflects only ongoing collaboration activity and increased royalty revenue, which remains minimal and highly dependent on future commercial sales of zanatumab—sales that have not yet materialized and face potential pricing pressure ex-U.S., as indirectly noted by Jazz’s MFN pricing headwinds commentary. Despite a $403.8 million cash position, the net loss widened to $44.2 million in Q1 FY26 from $22.6 million in Q1 FY25, primarily due to the revenue decline, and while the company cites disciplined OpEx management, the increase in unallocated costs related to leadership transition and only partial offset from reduced third-party program costs suggest underlying cost discipline may be eroding as the organization scales its leadership and R&D investments simultaneously.
The pan-RAS ADC platform, while scientifically intriguing, faces substantial translational hurdles that management did not adequately address, including the inherent complexity of developing ADC payloads targeting intracellular proteins like RAS, which requires efficient internalization, endosomal escape, and cytosolic delivery—none of which were quantified in the preclinical data presented. The company’s reliance on DAR-8 ADCs to estimate relative payload delivery and their avoidance of direct mole-to-mole comparisons with small-molecule inhibitors suggest a lack of confidence in demonstrating comparable intracellular target engagement, raising questions about whether the observed tumor accumulation and pathway inhibition (via DUSP6 levels) truly translate to meaningful antiproliferative effects at clinically achievable doses. Furthermore, the focus on xenograft models, which lack human stroma and immune components, limits the generalizability of the durability claims, and the absence of any discussion regarding payload stability, linker efficacy in vivo, or manufacturing scalability for novel pan-RAS inhibitors indicates that these programs remain highly speculative, with IND filing timelines for 2027 implicitly acknowledged through the deferral of ZW1528 and no concrete dates provided for the RAS ADCs despite claims of being “well positioned.”
ZW191’s clinical activity, while encouraging in heavily pretreated populations, may not be sufficient to support broad commercial viability, particularly given the lack of biomarker-driven patient selection and the observation of activity regardless of FRα expression, which complicates trial design, increases development costs, and risks dilution of efficacy signals in larger Phase 2/3 studies. The company’s acknowledgment that dose optimization is ongoing in a 60-patient cohort—despite prior reporting of full enrollment—suggests uncertainty in defining the optimal therapeutic window, and while they cite flexibility to refine tolerability without compromising activity, the absence of any discussion regarding combination trial initiation or partnership pursuit beyond vague statements about evaluating options implies internal resource constraints may limit their ability to independently generate the robust data package needed for regulatory approval or value-accretive external collaboration. Furthermore, the broader TriTCE and pasotuxizumab programs, while cited as long-term value drivers, remain preclinical or early-stage with no near-term data catalysts, and the company’s repeated emphasis on optionality and partnership dependence for advancing assets like ZW191 signals a lack of conviction in solo execution, which could deter investors seeking self-sufficient growth engines.

Statistical Measurement Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Customer Breakdown of Revenue (2025)

Statistical Measurement Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Customer Breakdown of Revenue (2025)

Statistical Measurement Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password